Search results for "Serotonin receptor"

showing 10 items of 39 documents

Serotonin Heteroreceptor Complexes and Their Integration of Signals in Neurons and Astroglia—Relevance for Mental Diseases

2021

The heteroreceptor complexes present a novel biological principle for signal integration. These complexes and their allosteric receptor–receptor interactions are bidirectional and novel targets for treatment of CNS diseases including mental diseases. The existence of D2R-5-HT2AR heterocomplexes can help explain the anti-schizophrenic effects of atypical antipsychotic drugs not only based on blockade of 5-HT2AR and of D2R in higher doses but also based on blocking the allosteric enhancement of D2R protomer signaling by 5-HT2AR protomer activation. This research opens a new understanding of the integration of DA and 5-HT signals released from DA and 5-HT nerve terminal networks. The biologica…

0301 basic medicineReviewheteroreceptor complexesTropomyosin receptor kinase BReceptor tyrosine kinasechemistry.chemical_compound0302 clinical medicineG protein-coupled receptorsserotonin receptorsReceptor Serotonin 5-HT2ABiology (General)astrogliabiologyChemistryMental DisordersBrainGeneral MedicineAntidepressive AgentsdepressionG protein-coupled receptors; astroglia; depression; heteroreceptor complexes; rapid antidepressant drugs; receptor tyrosine kinase; serotonin receptors.medicine.symptomAntipsychotic AgentsSerotonergic NeuronsSignal TransductionProto-oncogene tyrosine-protein kinase Srcserotonin receptorheteroreceptor complexeQH301-705.5Astroglia; Depression; G protein-coupled receptors; Heteroreceptor complexes; Rapid antidepressant drugs; Receptor tyrosine kinase; Serotonin receptors;Allosteric regulationserotonin receptors heteroreceptor complexes depression astroglia receptor tyrosine kinase rapid antidepressant drugs G protein-coupled receptors.depression astroglia receptor tyrosine kinase rapid antidepressant drugs G protein-coupled receptorsHeteroreceptorNO03 medical and health sciencesmedicineAnimalsHumansReceptor Fibroblast Growth Factor Type 1rapid antidepressant drugsG protein-coupled receptorReceptors Dopamine D2Dopaminergic NeuronsTyrosine phosphorylationReceptor Cross-TalkReceptor Galanin Type 1Receptor Galanin Type 2030104 developmental biologyMechanism of actionAstrocytesreceptor tyrosine kinasebiology.proteinReceptors Serotonin 5-HT1Neuroscience030217 neurology & neurosurgeryCells
researchProduct

The impact of a worksite migraine intervention program on work productivity, productivity costs, and non-workplace impairment among Spanish postal se…

2004

Migraine is associated with a significant productivity loss to employers, who may benefit from making a migraine intervention available to their employees.To evaluate changes in migraine-related productivity and non-workplace impairment associated with a migraine intervention program from the employer perspective.This was a pre-test post-test study of Spanish Postal Service employees with migraine. The intervention consisted of counseling from occupational health physicians and rizatriptan 10 mg for symptomatic treatment of two subsequent migraine headaches. Physicians also prescribed additional medications for migraine prophylaxis, treatment of tension headaches, and rescue medications. Mi…

AdultCounselingMalemedicine.medical_specialtyMigraine DisordersMEDLINEOccupational Health ServicesEfficiencyOccupational safety and healthIntervention (counseling)AbsenteeismmedicineHumansPostal ServicePsychiatryProductivitybusiness.industryGeneral MedicineTriazolesmedicine.diseaseRizatriptanTryptaminesSerotonin Receptor AgonistsMigraineSpainAbsenteeismCosts and Cost AnalysisFemaleHeadachesmedicine.symptombusinessmedicine.drugFollow-Up StudiesCurrent medical research and opinion
researchProduct

A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine

2011

The objective of this study was to evaluate patients’ satisfaction with acute treatment of migraine with frovatriptan or almotriptan by preference questionnaire. One hundred and thirty three subjects with a history of migraine with or without aura (IHS 2004 criteria), with at least one migraine attack in the preceding 6 months, were enrolled and randomized to frovatriptan 2.5 mg or almotriptan 12.5 mg, treating 1–3 attacks. The study had a multicenter, randomized, double blind, cross-over design, with treatment periods lasting <3 months. At study end patients assigned preference to one of the treatments using a questionnaire with a score from 0 to 5 (primary endpoint). Secondary endpoints w…

AdultMaleAdolescentOriginalMigraine with AuraPopulationAlmotriptanCarbazolesClinical NeurologyMigraine; almotriptan; FrovatriptanYoung Adultalmotriptan; frovatriptan; migraine; patient preferenceDouble-Blind MethodAlmotriptanmedicineHumansMigraine Frovatriptan Almotriptan Patient preferencePatient preferenceeducationMigraineAgededucation.field_of_studyCross-Over Studiesbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseCrossover studyRizatriptanTryptaminesMigraine with auraSerotonin Receptor AgonistsalmotriptanTreatment OutcomeAnesthesiology and Pain MedicineItalyMigraineTolerabilityAnesthesiaAcute DiseaseFemaleSettore MED/26 - NeurologiaNeurology (clinical)medicine.symptombusinessFrovatriptanFrovatriptanmedicine.drug
researchProduct

Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine : a phase 2 randomised, placebo-control…

2012

Lasmiditan (COL-144) is a novel, centrally acting, highly selective 5-HT(1F) receptor agonist without vasoconstrictor activity that seemed effective when given as an intravenous infusion in a proof-of-concept migraine study. We aimed to assess the efficacy and safety of oral lasmiditan for the acute treatment of migraine.In this multicentre, double-blind, parallel-group, dose-ranging study in 43 headache centres in five European countries, patients with migraine with and without aura and who were not using prophylaxis were randomly assigned (1:1:1:1:1) to treat one moderate or severe attack at home with 50 mg, 100 mg, 200 mg, or 400 mg lasmiditan, or placebo. Study drug and placebo were sup…

AdultMaleDrug-Related Side Effects and Adverse ReactionsPyridinesPopulationMedizinAdministration OralKaplan-Meier EstimatePlacebolaw.inventionYoung Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodPiperidinesRandomized controlled triallawHumansMedicineAdverse effecteducationAgededucation.field_of_studyDose-Response Relationship Drugbusiness.industryMiddle AgedDose-ranging studymedicine.diseaseLasmiditanSerotonin Receptor Agonists3. Good healthTreatment OutcomechemistryTolerabilityMigraine030220 oncology & carcinogenesisAnesthesiaBenzamidesFemaleNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

Zolmitriptan inhibits neurogenic inflammation and pain during electrical stimulation in human skin.

2014

Background Triptans are agonists to 5-HT 1B/D/F receptors, which are present on nociceptive neurons not only within but also beyond the trigeminal system. The aim of this study was to investigate whether zolmitriptan interacts with peptidergic nociceptive afferents in human skin. Methods Twenty participants (13 women, median age: 25; interquartile range: 23–26 years) entered the randomized, double-blind, cross-over study. Electrically induced neurogenic flare and pain was assessed after either placebo or zolmitriptan on the ventral thigh. Mechanical pain thresholds were investigated at baseline and after electrical stimulation at the stimulation site. Results The size of the neurogenic flar…

AdultMalePain ThresholdMigraine DisordersPainStimulationZolmitriptanHuman skinTriptansPharmacologyPlaceboYoung AdultDouble-Blind MethodPhysical StimulationmedicineHumansNeurons AfferentOxazolidinonesPain MeasurementSkinNeurogenic inflammationCross-Over Studiesbusiness.industryNociceptorsElectric StimulationTryptaminesSerotonin Receptor AgonistsAnesthesiology and Pain MedicineNociceptionAnesthesiaHyperalgesiaFemalemedicine.symptomNeurogenic Inflammationbusinessmedicine.drugEuropean journal of pain (London, England)
researchProduct

Activation of the cortical pain network by soft tactile stimulation after injection of sumatriptan.

2006

The anti-migraine drug sumatriptan often induces unpleasant somatosensory side effects, including a dislike of being touched. With a double-blind cross-over design, we studied the effects of sumatriptan and saline on perception (visual analogue scale) and cortical processing (functional magnetic resonance imaging) of tactile stimulation in healthy subjects. Soft brush stroking on the calf (n = 6) was less pleasant (p < 0.04) and evoked less activation of posterior insular cortex in the sumatriptan compared to the saline condition. Soft brushing activated pain processing regions (anterior insular, lateral orbitofrontal, and anterior cingulate cortices, and medial thalamus) only in the sumatr…

AdultMalePain ThresholdPainStimulationSomatosensory systemInsular cortexDouble-Blind MethodPhysical StimulationmedicineImage Processing Computer-AssistedHumansPain MeasurementSkinCerebral CortexBrain MappingSensory stimulation therapyCross-Over Studiesmedicine.diagnostic_testSumatriptanMagnetic Resonance ImagingSerotonin Receptor AgonistsOxygenSumatriptanAnesthesiology and Pain MedicineNociceptionNeurologyTouchNociceptorFemaleNeurology (clinical)Functional magnetic resonance imagingPsychologyNeurosciencemedicine.drugPain
researchProduct

Preference for Rizatriptan 10-mg Wafer vs. Eletriptan 40-mg Tablet for Acute Treatment of Migraine

2006

Preference is a composite, patient-oriented endpoint incorporating efficacy, tolerability, formulation, and convenience of medications. The objective of this study was to compare patient preference for rizatriptan 10-mg wafer vs. eletriptan 40-mg tablet for acute treatment of migraine. In this multicentre, open-label, two-period, crossover study, out-patients were randomly assigned to treat the first of two moderate to severe migraines with rizatriptan or eletriptan and the second with the alternate therapy. Patients completed diary assessments at baseline and up to 24 h after taking study medication. At the last visit, patients completed a psychometrically validated preference questionnai…

AdultMalePyrrolidinesTime FactorsAdolescentMigraine DisordersAdministration OralTriptanslaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawmedicineHumans030212 general & internal medicineEletriptanAgedbusiness.industryGeneral MedicineMiddle AgedTriazolesmedicine.diseaseCrossover studyRizatriptanTryptaminesConfidence intervalSerotonin Receptor AgonistsMigraineTolerabilityPatient SatisfactionAnesthesiaFemaleNeurology (clinical)business030217 neurology & neurosurgeryTabletsmedicine.drugCephalalgia
researchProduct

Stratified Care vs Step Care Strategies for Migraine

2000

ContextVarious guidelines recommend different strategies for selecting and sequencing acute treatments for migraine. In step care, treatment is escalated after first-line medications fail. In stratified care, initial treatment is based on measurement of the severity of illness or other factors. These strategies for migraine have not been rigorously evaluated.ObjectiveTo compare the clinical benefits of 3 strategies: stratified care, step care within attacks, and step care across attacks, among patients with migraine.Design and SettingRandomized, controlled, parallel-group clinical trial conducted by the Disability in Strategies Study group from December 1997 to March 1999 in 88 clinical cen…

AdultMalemedicine.medical_specialtyMetoclopramideMigraine DisordersPopulationZolmitriptanSeverity of Illness IndexDrug Administration Schedulelaw.inventionRandomized controlled triallawInternal medicineSeverity of illnessHumansMedicineeducationOxazolidinonesAspirineducation.field_of_studyAspirinbusiness.industryAnti-Inflammatory Agents Non-SteroidalArea under the curveGeneral MedicineMiddle Agedmedicine.diseaseTryptaminesSerotonin Receptor AgonistsClinical trialMigraineCritical PathwaysPhysical therapyDopamine AntagonistsFemalebusinessmedicine.drugJAMA
researchProduct

Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, …

2012

The objective of the study was to compare the efficacy and safety of frovatriptan and almotriptan in women with menstrually related migraine (IHS Classification of Headache disorders) enrolled in a multicenter, randomized, double-blind, cross-over study. Patients received frovatriptan 2.5 mg or almotriptan 12.5 mg in a randomized sequence: after treating 3 episodes of migraine in no more than 3 months with the first treatment, the patient was switched to the other treatment. 67 of the 96 female patients of the intention-to-treat population of the main study had regular menstrual cycles and were thus included in this subgroup analysis. 77 migraine attacks classified as related to menses were…

AdultTime FactorsOriginalMigraine DisordersPopulationAlmotriptanClinical NeurologyCarbazolesSubgroup analysisSeverity of Illness IndexAdult; Carbazoles; Cross-Over Studies; Disability Evaluation; Double-Blind Method; Female; Humans; Italy; Menstruation Disturbances; Middle Aged; Migraine Disorders; Proportional Hazards Models; Serotonin Receptor Agonists; Severity of Illness Index; Time Factors; Treatment Outcome; TryptaminesDisability EvaluationDouble-Blind MethodAlmotriptanSeverity of illnessMedicineHumanseducationMigraine Menstrually related migraine Frovatriptan AlmotriptanMenstrually related migraineMenstruation DisturbancesMigraineMenstrually related migraineProportional Hazards Modelseducation.field_of_studyCross-Over Studiesbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseCrossover studyTryptaminesSerotonin Receptor Agonistsfrovatriptan; migraine; menstrually related migraine; almotriptanAnesthesiology and Pain MedicineTreatment OutcomeMigraineItalyAnesthesiaFemaleNeurology (clinical)businessFrovatriptanFrovatriptanmedicine.drug
researchProduct

Locomotor and antidepressant-like effects of 5-HT(1A) agonist LY 228729 in prenatally benzodiazepine-exposed rats.

1998

Locomotor activity and antidepressant-like effect in the forced swim test (FST) of 5-HT(1A) agonist LY 228729 were investigated in adult rats prenatally exposed at doses of diazepam (DZ) and alprazolam (ALP) which induce persistent downregulation of GABA/ benzodiazepine (BZ) receptors. Prenatal exposure to ALP and DZ did not modify the efficacy of subchronic LY 228729 to decrease immobility time in the FST. Prenatal DZ and ALP potentiated the facilitatory effect of subchronic LY 228729 on locomotor activity; prenatal DZ was more effective than prenatal ALP. Moreover, prenatal DZ increased stereotypic movements induced by LY 228729. These data suggest that the persistent downregulation of GA…

AgonistMalemedicine.drug_classInjections SubcutaneousPharmacologyMotor ActivityRats Sprague-DawleyDownregulation and upregulationPregnancymedicineAnimalsPharmacology (medical)ErgolinesReceptorBiological Psychiatry5-HT receptorSwimmingPharmacologyBenzodiazepineDepressive DisorderDiazepamAlprazolamChemistrymusculoskeletal neural and ocular physiologyAntidepressive AgentsRatsSerotonin Receptor AgonistsPsychiatry and Mental healthNeurologyAlprazolamAnti-Anxiety AgentsPrenatal Exposure Delayed EffectsFemaleNeurology (clinical)Stereotyped Behaviorhuman activitiesDiazepammedicine.drugBehavioural despair testEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
researchProduct